Published in Medical Letter on the CDC and FDA, October 16th, 2005
Product rollout in the United States will commence immediately following the receipt of a final approval order, which Biomet projects will be issued by the end of calendar 2005.
"The introduction of the C2a-Taper Acetabular System will further enhance Biomet's hip articulation portfolio and offer surgeons who prefer ceramic-on-ceramic technology a compelling design," noted Biomet President and CEO Dane A. Miller, PhD. "The C2a-Taper Acetabular System features Biomet's Porous Plasma Spray (PPS)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.